The estimated Net Worth of Brendan P. O'grady is at least $5.17 Million dollars as of 4 March 2021. Mr. grady owns over 19,608 units of Teva- Pharmaceutical Industries stock worth over $267,029 and over the last 7 years he sold TEVA stock worth over $1,436,179. In addition, he makes $3,462,290 as Executive Vice President - North America Commercial at Teva- Pharmaceutical Industries.
Brendan has made over 8 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 19,608 units of TEVA stock worth $207,060 on 4 March 2021.
The largest trade he's ever made was selling 73,127 units of Teva- Pharmaceutical Industries stock on 28 February 2021 worth over $797,816. On average, Brendan trades about 7,825 units every 28 days since 2018. As of 4 March 2021 he still owns at least 14,868 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. grady stock trades at the bottom of the page.
Brendan P. O'Grady serves as Executive Vice President - North America Commercial of the Company. Mr. O’Grady was appointed Executive Vice President, North America Commercial in November 2017. From 2016 to November 2017, he served as Chief Commercial Officer, Global Specialty Medicines and served as interim head of Teva’s European Specialty business. Prior to that, he held various senior roles since joining Teva in 2011 as Regional Account Manager, and from 2015 to 2016, he served as President and CEO, Teva North America Generics. Prior to joining Teva, Mr. O’Grady spent ten years with Sanofi predecessor companies in a variety of commercial and medical affairs roles that began in field sales. Mr. O’Grady has been serving on the science and technology committee and on the policy committee of the Association for Accessible Medicines since 2017 and, in September 2019, he was appointed to serve on the U.S. Investment Advisory Council.
As the Executive Vice President - North America Commercial of Teva- Pharmaceutical Industries, the total compensation of Brendan Grady at Teva- Pharmaceutical Industries is $3,462,290. There are 4 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Brendan Grady is 53, he's been the Executive Vice President - North America Commercial of Teva- Pharmaceutical Industries since 2017. There are 16 older and 11 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Brendan's mailing address filed with the SEC is ASSERTIO HOLDINGS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST, IL, 60045.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks, and Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: